- Latest Stories
- Commentary and Analysis
11:31AM ET 5/24/2022 MT NewswiresMagenta Therapeutics (MGTA) has an average buy rating among analysts, with a price target range of $2 to $20. (MT Newswires covers equity, commodity and...
12:51PM ET 5/16/2022 MT NewswiresMagenta Therapeutics (MGTA) has an average rating of Buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...
1:32PM ET 4/18/2022 MT NewswiresMagenta Therapeutics (MGTA) shares were down almost 10% on Monday afternoon after a series of price-target cuts. Mizuho Securities cut the price target to...
7:34AM ET 4/18/2022 MT NewswiresMagenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...
7:26AM ET 4/18/2022 MT NewswiresMagenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...
3:56PM ET 4/14/2022 MT NewswiresHealth care stocks were narrowly lower this afternoon, with the NYSE Health Care Index slipping 0.1% and the SPDR Health Care Select Sector ETF (XLV) down...
1:08PM ET 4/14/2022 MT NewswiresHealth care stocks were narrowly lower this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) down 0.2%. The...
12:16PM ET 4/14/2022 MT NewswiresMagenta Therapeutics (MGTA) has an average rating of Buy and price targets ranging from $6 to $17, according to analysts polled by Capital IQ. (MT...
10:08AM ET 4/14/2022 MT NewswiresMagenta Therapeutics (MGTA) said Thursday it is planning to focus capital spending on its ongoing development of MGTA-117 as a potential treatment for...
1:56PM ET 3/08/2022 MT NewswiresMagenta Therapeutics (MGTA) has an average rating of Buy and price targets ranging from $6 to $20, according to analysts polled by Capital IQ. (MT...